Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venglustat in ERT-naïve Fabry disease
NCT02228460Phase 2Completed
- Sponsor
- Sanofi
- Start
- Nov 2014
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of venglustat in Fabry disease (FD), sponsored by Sanofi. Primary endpoint: Change From Baseline at Week 26 in Skin Globotriaosylceramide (GL-3) Score in Superficial Skin Capillary Endothelium. Started Nov 2014; status: completed.
02
Drugs
venglustat
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NCT02228460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02228460.